Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Robert Erik Holmlin M.B.A., Ph.D. | President, CEO & Director and CFO | 612.62k | -- | 1968 |
| Mr. Mark Oldakowski | Chief Operating Officer | 472.91k | -- | 1974 |
| Dr. Alka Chaubey FACMG, Ph.D. | Chief Medical Officer | 452.91k | -- | 1973 |
| Mr. Mark Adamchak CPA | VP of Accounting & Controller | -- | -- | -- |
| Mr. Jonathan Dixon J.D. | General Counsel & Secretary | -- | -- | 1975 |
| Mr. Stanislas Marin M.B.A., M.S. | Vice President of Global Sales | -- | -- | -- |
| Ms. Donna Polizio | Global Head of Market Access | -- | -- | -- |
| Mr. Cory Kreeck | Global Head of People Operations | -- | -- | -- |
Bionano Genomics, Inc.
- Sector:
- Healthcare
- Industry: Medical Instruments & Supplies
- Full Time Employees:
- 344
Description
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Corporate Governance
Upcoming Events
March 3, 2025 at 9:00 PM UTC - March 7, 2025 at 9:00 PM UTC
Bionano Genomics, Inc. Earnings Date